Intra-Cellular Therapies Inc (ITCI)
66.90
+1.19
(+1.81%)
USD |
NASDAQ |
May 15, 15:29
Intra-Cellular Therapies Cash from Operations (Quarterly): -34.12M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -34.12M |
| December 31, 2023 | -2.061M |
| September 30, 2023 | -25.27M |
| June 30, 2023 | -36.80M |
| March 31, 2023 | -60.07M |
| December 31, 2022 | -39.19M |
| September 30, 2022 | -53.35M |
| June 30, 2022 | -94.79M |
| March 31, 2022 | -82.85M |
| December 31, 2021 | -73.18M |
| September 30, 2021 | -79.27M |
| June 30, 2021 | -59.33M |
| March 31, 2021 | -47.77M |
| December 31, 2020 | -68.24M |
| September 30, 2020 | -63.58M |
| June 30, 2020 | -47.02M |
| March 31, 2020 | -51.23M |
| December 31, 2019 | -35.06M |
| September 30, 2019 | -29.99M |
| June 30, 2019 | -27.31M |
| March 31, 2019 | -35.63M |
| Date | Value |
|---|---|
| December 31, 2018 | -29.16M |
| September 30, 2018 | -28.41M |
| June 30, 2018 | -33.61M |
| March 31, 2018 | -26.98M |
| December 31, 2017 | -24.79M |
| September 30, 2017 | -14.41M |
| June 30, 2017 | -24.89M |
| March 31, 2017 | -16.40M |
| December 31, 2016 | -28.45M |
| September 30, 2016 | -29.66M |
| June 30, 2016 | -13.50M |
| March 31, 2016 | -19.65M |
| December 31, 2015 | -35.06M |
| September 30, 2015 | -20.51M |
| June 30, 2015 | -31.00M |
| March 31, 2015 | -15.71M |
| December 31, 2014 | -6.206M |
| September 30, 2014 | -4.420M |
| June 30, 2014 | -5.198M |
| March 31, 2014 | -6.983M |
| June 30, 2013 | -0.0099M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-94.79M
Minimum
Jun 2022
-2.061M
Maximum
Dec 2023
-50.52M
Average
-49.50M
Median
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 3.657B |
| Insmed Inc | -184.04M |
| Madrigal Pharmaceuticals Inc | -149.16M |
| Vertex Pharmaceuticals Inc | 1.307B |
| Fate Therapeutics Inc | -33.35M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 16.18M |
| Cash from Financing (Quarterly) | 9.989M |
| Free Cash Flow | -98.25M |
| Free Cash Flow Per Share (Quarterly) | -0.3522 |
| Free Cash Flow to Equity (Quarterly) | -34.12M |
| Free Cash Flow to Firm (Quarterly) | -34.12M |
| Free Cash Flow Yield | -1.52% |